Novo Nordisk A/S Stock Forecast, Price & News

Novo Nordisk A/S (NYSE:NVO) Frequently Asked Questions

Is Novo Nordisk A/S a buy right now?

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Novo Nordisk A/S in the last twelve months. There are currently 2 sell ratings, 8 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Novo Nordisk A/S stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVO, but not buy additional shares or sell existing shares.
View analyst ratings for Novo Nordisk A/S or view top-rated stocks.

How has Novo Nordisk A/S's stock price been impacted by COVID-19 (Coronavirus)?

Novo Nordisk A/S's stock was trading at $57.89 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, NVO shares have increased by 66.4% and is now trading at $96.32.
View which stocks have been most impacted by COVID-19.

Are investors shorting Novo Nordisk A/S?

Novo Nordisk A/S saw a increase in short interest during the month of December. As of December 31st, there was short interest totaling 2,810,000 shares, an increase of 42.6% from the December 15th total of 1,970,000 shares. Based on an average trading volume of 1,130,000 shares, the days-to-cover ratio is currently 2.5 days. Approximately 0.2% of the shares of the company are short sold.
View Novo Nordisk A/S's Short Interest.

When is Novo Nordisk A/S's next earnings date?

Novo Nordisk A/S is scheduled to release its next quarterly earnings announcement on Wednesday, February 2nd 2022.
View our earnings forecast for Novo Nordisk A/S.

How were Novo Nordisk A/S's earnings last quarter?

Novo Nordisk A/S (NYSE:NVO) issued its quarterly earnings results on Tuesday, November, 2nd. The company reported $5.27 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.78 by $4.49. The company had revenue of $5.65 billion for the quarter, compared to analysts' expectations of $5.64 billion. Novo Nordisk A/S had a net margin of 34.33% and a trailing twelve-month return on equity of 73.70%.
View Novo Nordisk A/S's earnings history.

How often does Novo Nordisk A/S pay dividends? What is the dividend yield for Novo Nordisk A/S?

Novo Nordisk A/S announced a semi-annual dividend on Friday, August 6th. Stockholders of record on Tuesday, August 17th will be given a dividend of $0.5571 per share on Wednesday, August 25th. This represents a yield of 1.1%. The ex-dividend date is Monday, August 16th.
View Novo Nordisk A/S's dividend history.

Is Novo Nordisk A/S a good dividend stock?

Novo Nordisk A/S pays an annual dividend of $0.77 per share and currently has a dividend yield of 0.80%. The dividend payout ratio of Novo Nordisk A/S is 23.99%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Novo Nordisk A/S will have a dividend payout ratio of 22.99% next year. This indicates that Novo Nordisk A/S will be able to sustain or increase its dividend.
View Novo Nordisk A/S's dividend history.

What guidance has Novo Nordisk A/S issued on next quarter's earnings?

Novo Nordisk A/S issued an update on its FY 2021 earnings guidance on Friday, November, 5th. The company provided EPS guidance of for the period. The company issued revenue guidance of $22.55 billion-$23.15 billion, compared to the consensus revenue estimate of $21.35 billion.

What price target have analysts set for NVO?

13 brokerages have issued 12 month price objectives for Novo Nordisk A/S's stock. Their forecasts range from $592.00 to $592.00. On average, they anticipate Novo Nordisk A/S's stock price to reach $592.00 in the next twelve months. This suggests a possible upside of 514.6% from the stock's current price.
View analysts' price targets for Novo Nordisk A/S or view top-rated stocks among Wall Street analysts.

Who are Novo Nordisk A/S's key executives?

Novo Nordisk A/S's management team includes the following people:

• Lars Fruergaard Jørgensen, President & Chief Executive Officer
• Maziar Mike Doustdar, Executive Vice President-International Operations
• Karsten Munk Knudsen, Chief Financial Officer & Executive Vice President
• Mads Krogsgaard Thomsen, Chief Science Officer & Executive Vice President
• Henrik Ehlers Wulff, Executive VP & Head-Information Technology

What is Lars Fruergaard Jørgensen's approval rating as Novo Nordisk A/S's CEO?

372 employees have rated Novo Nordisk A/S CEO Lars Fruergaard Jørgensen on Glassdoor.com. Lars Fruergaard Jørgensen has an approval rating of 92% among Novo Nordisk A/S's employees. This puts Lars Fruergaard Jørgensen in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Novo Nordisk A/S's key competitors?

Some companies that are related to Novo Nordisk A/S include Johnson & Johnson (JNJ), Roche (RHHBY), Pfizer (PFE), AbbVie (ABBV), Eli Lilly and (LLY), Abbott Laboratories (ABT), Merck & Co., Inc. (MRK), Novartis (NVS), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Sanofi (SNY), GlaxoSmithKline (GSK), Zoetis (ZTS), CSL (CSLLY) and Regeneron Pharmaceuticals (REGN).
View all of NVO's competitors.

What other stocks do shareholders of Novo Nordisk A/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novo Nordisk A/S investors own include Gilead Sciences (GILD), AbbVie (ABBV), Pfizer (PFE), NVIDIA (NVDA), Johnson & Johnson (JNJ), Alibaba Group (BABA), QUALCOMM (QCOM), Cisco Systems (CSCO), AT&T (T) and Abbott Laboratories (ABT).

What is Novo Nordisk A/S's stock symbol?

Novo Nordisk A/S trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVO."

Who are Novo Nordisk A/S's major shareholders?

Novo Nordisk A/S's stock is owned by a number of retail and institutional investors. Top institutional investors include Scout Investments Inc. (0.01%), First American Trust FSB (0.00%), Wedbush Securities Inc. (0.00%), Crossmark Global Holdings Inc. (0.00%), Confluence Investment Management LLC (0.00%) and Carroll Financial Associates Inc. (0.00%).
View institutional ownership trends for Novo Nordisk A/S.

Which institutional investors are selling Novo Nordisk A/S stock?

NVO stock was sold by a variety of institutional investors in the last quarter, including Moody National Bank Trust Division, First American Trust FSB, Perkins Coie Trust Co, Scout Investments Inc., Koshinski Asset Management Inc., Confluence Investment Management LLC, Gradient Investments LLC, and IFP Advisors Inc.
View insider buying and selling activity for Novo Nordisk A/S or view top insider-selling stocks.

Which institutional investors are buying Novo Nordisk A/S stock?

NVO stock was purchased by a variety of institutional investors in the last quarter, including Neville Rodie & Shaw Inc., Stonnington Group LLC, Five Oceans Advisors, Private Trust Co. NA, Shilanski & Associates Inc., Stratos Wealth Partners LTD., First Hawaiian Bank, and Chesley Taft & Associates LLC.
View insider buying and selling activity for Novo Nordisk A/S or or view top insider-buying stocks.

How do I buy shares of Novo Nordisk A/S?

Shares of NVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Novo Nordisk A/S's stock price today?

One share of NVO stock can currently be purchased for approximately $96.32.

How much money does Novo Nordisk A/S make?

Novo Nordisk A/S has a market capitalization of $226.81 billion and generates $19.45 billion in revenue each year. The company earns $6.46 billion in net income (profit) each year or $3.21 on an earnings per share basis.

How many employees does Novo Nordisk A/S have?

Novo Nordisk A/S employs 45,323 workers across the globe.

Does Novo Nordisk A/S have any subsidiaries?

The following companies are subsidiares of Novo Nordisk A/S: Aldaph SpA, Beijing Novo Nordisk Pharmaceuticals Science & Technology Co. Ltd., Calibrium, Churchill Stateside Solar Fund XIV LLC, Corvidia, Emisphere Technologies, MB2 LLC, NNE A/S, Novo Investment Pte Limited, Novo Nordisk, Novo Nordisk (China) Pharmaceuticals Co. Ltd., Novo Nordisk (Pty) Limited, Novo Nordisk B.V., Novo Nordisk Biopharm Limited, Novo Nordisk Canada Inc., Novo Nordisk Colombia SAS, Novo Nordisk Comercio Produtos Farmaceuticos Lda., Novo Nordisk Denmark A/S, Novo Nordisk Egypt LLC, Novo Nordisk Farma OY, Novo Nordisk Farma S.R.L., Novo Nordisk Farma dooel, Novo Nordisk Farmacéutica Limitada, Novo Nordisk Farmacêutica do Brasil Ltda., Novo Nordisk Health Care AG, Novo Nordisk Hellas Epe., Novo Nordisk Holding Limited, Novo Nordisk Hong Kong Limited, Novo Nordisk Hrvatska d.o.o., Novo Nordisk Hungaria Kft., Novo Nordisk Inc., Novo Nordisk India Private Limited, Novo Nordisk Kazakhstan LLP, Novo Nordisk Kenya Ltd., Novo Nordisk Lanka (PVT) Ltd, Novo Nordisk Limited, Novo Nordisk Limited Liability Company, Novo Nordisk Ltd, Novo Nordisk Mexico S.A. de C.V., Novo Nordisk Panama S.A., Novo Nordisk Pars, Novo Nordisk Peru S.A.C., Novo Nordisk Pharma (Malaysia) Sdn Bhd, Novo Nordisk Pharma (Private) Limited, Novo Nordisk Pharma (Singapore) Pte Ltd., Novo Nordisk Pharma (Taiwan) Ltd., Novo Nordisk Pharma (Thailand) Ltd., Novo Nordisk Pharma AG, Novo Nordisk Pharma Argentina S.A., Novo Nordisk Pharma EAD, Novo Nordisk Pharma GmbH, Novo Nordisk Pharma Gulf FZ-LLC, Novo Nordisk Pharma Inc., Novo Nordisk Pharma Korea Ltd., Novo Nordisk Pharma Limited, Novo Nordisk Pharma Ltd., Novo Nordisk Pharma Operations (Business Area) Sdn Bhd, Novo Nordisk Pharma Operations A/S, Novo Nordisk Pharma S.A., Novo Nordisk Pharma SARL, Novo Nordisk Pharma SAS, Novo Nordisk Pharma d.o.o., Novo Nordisk Pharma d.o.o. Belgrade (Serbia), Novo Nordisk Pharmaceutical Industries LP, Novo Nordisk Pharmaceutical Services Sp. z o.o., Novo Nordisk Pharmaceuticals (Philippines) Inc., Novo Nordisk Pharmaceuticals Ltd., Novo Nordisk Pharmaceuticals Pty. Ltd., Novo Nordisk Pharmatech A/S, Novo Nordisk Production SAS, Novo Nordisk Production Support LLC, Novo Nordisk Produção Farmacêutica do Brasil Ltda., Novo Nordisk Region AAMEO and LATAM A/S, Novo Nordisk Region Europe A/S, Novo Nordisk Region Japan & Korea A/S, Novo Nordisk Research Center Indianapolis Inc., Novo Nordisk Research Center Seattle Inc., Novo Nordisk S.P.A., Novo Nordisk Saglik Ürünleri Tic. Ltd. Sti., Novo Nordisk Scandinavia AB, Novo Nordisk Scandinavia AS, Novo Nordisk Service Centre (India) Pvt. Ltd., Novo Nordisk Slovakia s.r.o., Novo Nordisk Tunisie SARL, Novo Nordisk US Bio Production Inc., Novo Nordisk US Holdings Inc., Novo Nordisk Ukraine LLC, Novo Nordisk Venezuela Casa de Representacion C.A., Novo Nordisk d.o.o., Novo Nordisk s.r.o., PT. Novo Nordisk Indonesia, S.A. Novo Nordisk Pharma N.V., UAB Novo Nordisk Pharma, Xellia Pharmaceuticals, and Ziylo.

When was Novo Nordisk A/S founded?

Novo Nordisk A/S was founded in 1923.

What is Novo Nordisk A/S's official website?

The official website for Novo Nordisk A/S is www.novonordisk.com.

Where are Novo Nordisk A/S's headquarters?

Novo Nordisk A/S is headquartered at Novo Alle, Bagsvaerd G7, 2880.

How can I contact Novo Nordisk A/S?

Novo Nordisk A/S's mailing address is Novo Alle, Bagsvaerd G7, 2880. The company can be reached via phone at (454) 444-8888, via email at [email protected], or via fax at 45-4449-0555.